UTILITY OF INFLAMMATORY MARKERS FOR TOCILIZUMAB IN COVID-19 PATIENTS: A SINGLE-SITE RETROSPECTIVE STUDY

Authors

  • Muhammad Amir Lady Reading Hospital
  • Usman Ali Department of Pharmacy, Lady Reading Hospital-MTI, Peshawar
  • Adan Javed Department of Endocrinology, Lady Reading Hospital-MTI, Peshawar
  • Jawad Ahmad Department of Pharmacy, Lady Reading Hospital-MTI, Peshawar

DOI:

https://doi.org/10.55519/JAMC-04-10565

Abstract

Background: Studies are available on the use of inflammatory biomarkers for profiling and patient prognosis, but literature for tocilizumab monitoring parameters is scarce. Thus, we aim to evaluate different inflammatory markers that can relate to the effectiveness of tocilizumab in hospitalized patients suffering from severe covid. Method: We analyzed a retrospective cohort of 227 patients who were admitted due to SAR-Co2 in one of the largest hospitals in Pakistan, Lady Reading Hospital. Using in-hospital mortality as the primary parameter for the effectiveness of tocilizumab. Wilcoxon rank-sum test, chi-square test and ROC curve analysis were performed to evaluate inflammatory biomarkers. The p- values less than 0.05 were considered statistically significant. Result: A total of 1639 tests were identified from 227 patients admitted to the hospital. CRP (28%), LDH (27.3%) were the most commonly prescribed and 40% of the total test were prescribed pre-dose. D-dimer, ferritin and CRP were found to have a clinically significant impact of the dose.  Conclusion: D-dimer, ferritin and LDH do not seem to relate proportionally with tocilizumab effectiveness. CRP can be utilized for monitoring tocilizumab effectiveness.

References

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382(18):1708–20.

López-Medrano F, Pérez-Jacoiste Asín MA, Fernández-Ruiz M, Carretero O, Lalueza A, Maestro de la Calle G, et al. Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study. Int J Infect Dis 2021;105:487–94.

Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med 2021;384(16):1503–16.

Wei Q, Lin H, Wei RG, Chen N, He F, Zou DH, et al. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. Infect Dis Poverty 2021;10(1):71.

Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis 2020;96:467–74.

Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 2020;26(10):1636–43.

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020;323(18):1824¬–36.

Parr JB. Time to Reassess Tocilizumab’s Role in COVID-19 Pneumonia. JAMA Intern Med 2021;181(1):12.

Amir M, Gafoor A, Iqbal Z, Ashraf S, Zeb S. Compassionate Use of Tocilizumab in Patients with Coronavirus Disease 2019 in a Low-resource Country, Pakistan: A Pilot Study. BIO Integr 2021;2(4):180–3.

Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021;397(10285):1637–45.

Quartuccio L, Benucci M, De Vita S. Answer to Vieira et al. “Cytokine profile as a prognostic tool in coronavirus disease 2019”. Joint Bone Spine 2020. Doi:10.1016/j.jbspin.2020.09.006. Joint Bone Spine 2021;88(1):105076.

Government of Pakistan, Ministry of National Health Services, Regulations & Coordination. Guidelines: Clinical Management Guidelines for COVID-19 Infections. 2020 [Internet]. [cited 2021 Aug 6]. Available from: https://storage.covid.gov.pk/new_guidelines/11December2020_20201211_Clinical_Management_Guidelines_for_COVID-19_infection_1204.pdf

Hill JA, Menon MP, Dhanireddy S, Wurfel MM, Green M, Jain R, et al. Tocilizumab in hospitalized patients with COVID‐19: Clinical outcomes, inflammatory marker kinetics, and safety. J Med Virol 2021;93(4):2270–80.

Soin AS, Kumar K, Choudhary NS, Sharma P, Mehta Y, Kataria S, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med 2021;9(5):511–21.

Wadaa-Allah A, Emhamed MS, Sadeq MA, Ben Hadj Dahman N, Ullah I, Farrag NS, et al. Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review. Ann Med 2021;53(1):318–34.

Infectious Diseases Society of America. IDSA Guidelines on the treatment and management of patients with COVID-19. [Internet]. [cited 2021 Aug 6]. Available from: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/

Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. Bethesda (MD): National Institutes of Health (US); 2021 [cited 2021 Aug 6]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK570371/

NICE. COVID-19 rapid guideline: Managing COVID-19 [Internet]. [cited 2021 Aug 6]. Available from: https://app.magicapp.org/#/guideline/L4Qb5n/section/jb45gn

Gupta S, Leaf DE. Tocilizumab in COVID-19: some clarity amid controversy. Lancet 2021;397(10285):1599–601.

Downloads

Published

2022-09-27

Most read articles by the same author(s)